Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0042963 (vomiting)
 31,883 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This multicentre, double-blind, randomized, placebo-controlled, parallel study was designed to evaluate the efficacy of combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) in the acute treatment of migraine attacks. A total of 266 patients, 18-65 years old, with two to six attacks of migraine with or without aura (IHS criteria) per month were included. The patients had to treat two migraine attacks with LAS-MCP (1620 mg lysine acetylsalicylate--the equivalent of 900 mg aspirin--combined with 10 mg metoclopramide) or placebo. The main outcome measure was headache relief (reduction in headache severity from grade 3 or 2--severe or moderate--to grade 1 or 0--mild or none) 2 h after treatment. LAS-MCP was superior to placebo for headache relief (56% vs 28%) and for the following secondary outcome measures: complete headache relief (18% vs 7%; p < 0.001), nausea (28% vs 44%; p < 0.001), vomiting (3% vs 11%; p = 0.001), use of rescue medication (47% vs 68%; p < 0.001), global efficacy judged as good or excellent (32% vs 14%; p < 0.001). The tolerability was considered as good in 94% of treated attacks in both groups. Combined oral lysine acetylsalicylate and metoclopramide is an effective and well-tolerated acute treatment of migraine attacks.
 ...
PMID:Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. 795 60

Migraine is a common medical condition affecting more than 10% of population in Poland. Acute migraine attacks are often associated with gastrointestinal symptoms ranging from mild nausea to vomiting. The present study was specifically designed to compare the efficacy of the combination of lysine acetylsalicylate and metoclopramide (1620 mg LAS + 10 mg MTC--Migpriv) and ergotamine plus caffeine (2 mg ERG + 200 mg CAF--Coffecorn forte) in the treatment of migraine headache and nausea. 98 patients with migraine meeting HIS criteria were randomized. The primary endpoint was the number of patients having headache relief and no nausea or vomiting two hours after the drug intake. Significantly more Migpriv treated patients than Coffecorn ones were free of headache two hours after drug administration (58.7% vs. 35.7% respectively: p<0.002). Reported adverse events were rare and transient. Migpriv was significantly more effective than Coffecorn forte in relieving the migraine attack symptoms.
 ...
PMID:[Comparison of the effectiveness of lysine acetylsalicylate and metoclopramide combination with ergotamine plus caffeine in the treatment of migraine attacks]. 1530 20

Migraine is a common medical condition affecting nearly 10% of population in Poland. The aim of the study was to evaluate the efficacy, tolerability and safety of migraine abortive treatment with the combination of lysine acetylsalicylate and metoclopramide (1620 mg LAS + 10 mg MTC--Migpriv). 1620 patients with migraine, meeting International Headache Society (IHS) criteria were included in the study. The aim of the study was also determination of the number of patients having headache relief and no nausea or vomiting two hours after the drug intake. In most patients the migraine symptoms disappeared after a single dose administration. Reported adverse events were rare and short lasting. The study showed that metoclopramide was well tolerated and effective at relieving migraine attack symptoms.
 ...
PMID:[Assessment of efficacy of migraine attack treatment with lysine acetylsalicylate and metoclopramide]. 1577 Nov 35